Abstract
Introduction Contrast-enhanced spectral mammography (CESM) is a functional imaging technique with comparable accuracy to MRI for loco-regional staging of breast cancer. This study assesses the cost impact of switching from CE-MRI to CESM for loco-regional staging of breast cancer from a public healthcare perspective.
Methods The CE-MRI cost was obtained from NHS reference cost. The CESM cost was calculated using a bottom-up approach including use of the machine, pump injector, contrast, image storage and clinical staff’s time for reporting and cannulation. The cost of upgrading existing machines to CESM or purchasing new mammographic machines were obtained via national procurement. Other costs were obtained from local pharmacy, published unit cost data, or estimated based on surveys.
Results For large health boards in Scotland (≥500 cancers diagnosed/annum), the cost savings of switching from CE-MRI to CESM range from £64,069 to £81,570. For small health boards (<500 cancers diagnosed/annum), the cost savings of switching from CE-MRI to CESM range from £6,453 to £23,953. The cost savings are most sensitive to the number of tests conducted per year, and whether the existing mammography machine can be upgraded to CESM or not.
Conclusion Switching from CE-MRI to CESM for loco-regional staging of breast cancer is likely to be cost saving for both large and small health boards in Scotland. Further research is urgently needed to confirm the non-inferiority of CESM to CE-MRI as a locoregional staging technique. The input data of this analysis can be updated when such results become available.
Highlights
Switching from CE-MRI to CESM for locoregional staging is likely to be cost saving
For large health boards, estimated annual savings range from £64,069 to £81,570
For a small health boards, estimated annual savings range from £6,453 to £23,953
Cost is driven by number of imaging studies and equipment upgrade vs replacement
Research to confirm the non-inferiority of CESM for locoregional staging is needed
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- CESM
- : Contrast enhanced spectral mammography
- CE-MRI
- : Contrast enhanced magnetic resonance imaging
- PSSRU
- : Personal Social Services Research Unit
- NHS
- : National Health Service
